PRLDPrelude Therapeutics Incvs its industry peers
A metric-by-metric comparison of Prelude Therapeutics Inc against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRLDThis | $307M#8 | — | 2.3x#10 | 25.3x#6 | 73.4%#2 | 21.8%#5 | -861.3%#6 | -74.4%#8 | — | — | -2.8%#5 | — |
| AVTX | $386M#1 | — | 0.9x#3 | 6535.6x#9 | -86.6%#9 | -122.8%#13 | -123601.7%#9 | -17.4%#3 | -19.3%#2 | — | — | — |
| AVIR | $342M#2 | — | 1.7x#8 | 1.0x#2 | 622.5%#1 | 6.0%#8 | -51.5%#2 | -77.4%#9 | — | — | 31.4%#3 | — |
| GALT | $340M#3 | — | — | — | — | 34.5%#3 | — | — | — | — | -43.8%#9 | — |
| IRD | $328M#4 | — | — | 23.1x#5 | 29.1%#3 | 13.8%#7 | -271.9%#5 | — | — | — | — | — |
| ENTA | $311M#5 | — | 3.1x#11 | 4.8x#4 | -3.4%#5 | 29.4%#4 | -130.7%#3 | -81.0%#10 | — | — | -1.3%#4 | — |
| EBS | $310M#6 | — | 1.0x#5 | 0.4x#1 | -28.8%#7 | 127.6%#1 | 13.5%#1 | 16.8%#1 | 9.9%#1 | 7#1 | -42.6%#8 | — |
| VOGX | $307M#7 | — | — | — | — | — | — | — | — | — | — | — |
| SPRY | $299M#9 | — | 23.9x#12 | 3.5x#3 | -5.5%#6 | -2241.8%#15 | -212.9%#4 | -1369.1%#13 | -177.6%#3 | — | -65.1%#13 | — |
| BNTC | $296M#10 | — | 1.7x#7 | — | -100.0%#10 | -20.6%#10 | — | -25.8%#6 | — | — | -46.6%#10 | — |
| MPLT | $292M#11 | 0.1x#1 | 0.8x#2 | — | — | -107.7%#12 | — | -46.3%#7 | — | — | -58.7%#12 | — |
| TTRX | $291M#12 | — | 423.9x#13 | — | — | -80.6%#11 | — | -465.0%#12 | — | — | 119.4%#2 | — |
| FULC | $286M#13 | — | 0.9x#4 | — | -100.0%#10 | -670.0%#14 | — | -24.1%#5 | — | — | -58.4%#11 | — |
| LYEL | $279M#14 | — | 1.2x#6 | 7742.9x#10 | -41.0%#8 | 20.0%#6 | -748344.4%#10 | -117.4%#11 | — | — | -30.6%#7 | — |
| CYPH | $277M#15 | 4.0x#2 | 2.0x#9 | 184.6x#8 | 0.0%#4 | 107.4%#2 | -2737.8%#8 | 3.6%#2 | — | — | 519.1%#1 | — |
| BIOA | $272M#16 | — | 0.7x#1 | 30.3x#7 | — | -13.4%#9 | -1031.5%#7 | -21.5%#4 | — | — | -20.1%#6 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice